Browse Studies — Arctuva

Phase 1

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pha…

Advanced or Metastatic Solid TumorsBreast CancerOvarian Cancer+10 more

Estimated

~$10 – $8,750

858 Therapeutics, Inc.NCT06395519

Phase 1

An Open-Label Phase 1 Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of PRTH-101 Alone or in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

The goal of this Open-Label Study is to evaluate the safety and tolerability of PRTH-101 alone or in combination with pembrolizumab in adults with advance or m…

Advanced or Metastatic Solid TumorsNon Small Cell Lung CancerNSCLC

Estimated

~$10 – $8,750

Incendia TherapeuticsNCT05753722

Phase 1

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ANS014004 as a Single Agent in Participants With Locally Advanced or Metastatic Solid Tumors

This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity o…

Locally Advanced or Metastatic Solid Tumors

Estimated

~$10 – $8,750

Avistone Biotechnology Co., Ltd.NCT06307795

Phase 1

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ANS03 as a Single Agent in Participants With Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration

This is a first-in-human Phase I, multi-center, open-label study of ANS03 in patients with advanced solid tumors. The study evaluates the safety, tolerability,…

Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration

Estimated

~$10 – $8,750

Avistone Biotechnology Co., Ltd.NCT06716138